Cardiometabolic & Bone | Adooq Bioscience

Cat. No.: A84979

CAS No.: 3035422-95-5

Asedebart

Synonyms: LuAG13909

Asedebart is a CHO-expressed human antibody that specifically targets Adrenocorticotropic hormone (ACTH) and functions as an antagonist to inhibit the binding of ACTH to its receptor. With a molecular weight of approximately 145 kDa, comprising a huIgG1 heavy chain and huκ light chain, Asedebart facilitates studies into inflammatory diseases, including psoriasis and ulcerative colitis. Its application as a research reagent offers valuable insights into ACTH-related pathways and therapeutic interventions.

View Details

Out of stock

All 3 sizes

Cat. No.: AT0087

CAS No.: 615258-40-7

Denosumab

Synonyms: AMG-162

Denosumab is a human monoclonal antibody specifically designed to target and bind to the receptor activator of nuclear factor kappa-B ligand (RANKL) with a dissociation constant (K_D) of 0.003 nM for human RANKL. By inhibiting the interaction between RANKL and its receptor, RANK, Denosumab effectively blocks the NF-κB signaling pathway, which is crucial in the regulation of bone metabolism and immune responses. This inhibition prevents bone resorption, a key factor in various bone diseases and disorders. Additionally, Denosumab has been observed to promote proliferation and spermatogenesis. This antibody is particularly useful in research focused on bone density regulation, osteoporosis, and related bone health studies.

In stock View Details

All 3 sizes

Cat. No.: AT0707

CAS No.: 1233956-13-2

Volagidemab

Synonyms: REMD-477; AMG-477

Volagidemab is a monoclonal antibody designed to act as an antagonist to the glucagon receptor (GCGR). This antibody is specifically developed for use in research focused on Type 1 Diabetes (T1D), providing a critical tool for investigating the role of GCGR in glucose regulation and diabetic pathology.

In stock View Details

All 3 sizes

Cat. No.: AT0786

CAS No.: 1610833-03-8

Burosumab

Synonyms: KRN23

Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions.

In stock View Details

All 3 sizes

Cat. No.: AT1062

CAS No.: 1643672-70-1

Frovocimab

Synonyms: LY 3015014

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.

In stock View Details

All 3 sizes

Cat. No.: AT1079

CAS No.: 1391726-30-9

Landogrozumab

Synonyms: LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab

Landogrozumab (LY2495655) is a humanized monoclonal antibody targeting myostatin, a protein known to inhibit muscle growth. By neutralizing myostatin, Landogrozumab has been shown to enhance muscle volume, hand grip strength, and overall muscle function. This antibody is primarily utilized in research focused on muscle wasting diseases, providing a valuable tool for investigating potential therapeutic interventions for conditions characterized by muscle degeneration and loss.

In stock View Details

All 3 sizes

Cat. No.: AT1143

CAS No.: 705287-60-1

Stamulumab

Synonyms: MYO-029

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.

In stock View Details

All 3 sizes